The efficacy of ciprofloxacin in eradicating pharyngeal colonization of Neisseria meningitidis was studied among army recruits in Finland. Ciprofloxacin (250 mg) efficacy against meningococci has been shown to be good, its MIC has ranged from 0.0005 to 0.008 ,ug/ml (3, 6), and its concentration in saliva after an oral dose of 250 mg has been more than 0.4 ,ug/ml 2 h later (7). In March 1986, 552 voluntary healthy recruits who were not on any antimicrobial therapy were selected from two garrisons for screening of meningococcal carriage. For this purpose, throat cultures were taken from them 4 weeks after the beginning of their military service.
Sulfonamides, minocycline, and rifampin have been used successfully to reduce meningococcal carrier rates of close contacts of patients with a meningococcal disease (5, 11) . However, sulfonamides have side effects, and several epidemics have been caused by strains resistant to sulfonamides (1, 2, 4, 9) . Minocycline and rifampin have been shown to reduce carrier rates temporarily by 62 and 78%, respectively, among army recruits (11) , results which are not fully satisfactory.
The aim of this study was Randomly numbered packages of four tablets of either ciprofloxacin or placebo were obtained from Bayer AG. The tablets of 250 mg were given to the recruits twice daily at morning and evening meals on days 3 and 4 after the sampling. The men were encouraged to report any feeling of illness during the medication or just after.
A total of 552 recruits were cultured for meningococcal carriage. The overall carrier rate was 38.6% (i.e., 213 carriers). All strains were very susceptible to ciprofloxacin, the MIC being 0.004 ,ug/ml or less for 136 strains (64%) and 0.008 ,ug/ml for the remaining 77 strains (36%). Thirty-nine percent of the 213 strains were groupable, and of these 45% were of group B. Almost identical figures of groupable and group B strains were seen among the 118 meningococci belonging to the recruits selected for the treatment groups.
One hundred twelve follow-up samples were obtained from the 120 treated recruits. The missing samples were equally divided in both treatment groups ( any medical reason for this. Two of these men were in the placebo group, and they took three out of four tablets. Being in the placebo group, they were considered to be valid cases for this carrier analysis. The third recruit was in the ciprofloxacin group, and he forgot (?) to take two tablets. His follow-up culture was positive for meningococci, but his original group B strain was changed to nongroupable. Of the 109 valid cases, 56 were treated with ciprofloxacin and 53 were treated with placebo.
The carrier rate was reduced by 96% in the ciprofloxacin group as only 2 of the 56 recruits in this treatment group had a positive culture for meningococci in the follow-up sample. In one of these two cases the follow-up strain was not of the same group he had in the beginning. In the other case the meningococci were nongroupable in both samples, and it is possible the same strain persisted although the ciprofloxacin MIC was 0.008 jxg/tml in the beginning and 0.015 ,ug/ml after the treatment.
The carrier rate was also reduced in the placebo group but only by 13 %. Ciprofloxacin MICs for the meningococci found before and after the treatment period were practically the same. Twenty-five (52%) of the total of 48 strains found in the follow-up samples were inhibited by 0.004 ,ug of ciprofloxacin per ml or less, and 20 (42%) were inhibited by 0.008 pug/ml. Two strains needed 0.015 pug of ciprofloxacin per ml and one needed 0.06 ,ug/ml for inhibition.
Three persons in each treatment group (5%) reported side effects. All six complained of slight diarrhea. In addition, one of the three persons in the ciprofloxacin group reported some nausea, and another in the same group had symptoms of "flu." None of these six persons wanted to discontinue the medication.
Chemoprophylaxis is often needed for close contacts in army units and even in smaller entities in situations when meningococcal infections occur, especially if vaccination is missing or the causative organism is not covered by vaccination.
According to the results of this study, ciprofloxacin seems to be a promising chemoprophylactic drug in reducing meningococcal carrier rates for a short period of time.
